Hikal Limited (HIKAL), a preferred long-term partner for leading global life sciences companies, announced its unaudited financial results for the quarter and year ended 30th September 2026. The company reported consolidated revenue of ₹434 crore, up 36% YoY, EBITDA of ₹45 crore, and PAT of ₹(6) crore compared to ₹(35) crore last year.

Pharmaceuticals Performance

The Pharmaceuticals business continued its recovery, driven by growth in the established API portfolio and new-product commercialization. Pharma revenue grew by 47% YoY to ₹278 crore in Q2 FY27, with improvement in EBIT margins. API volumes recovered, while CDMO programmes and the customer pipeline expanded across the US, Europe, and Japan.

Crop Protection Performance

Crop Protection revenues for the quarter stood at ₹156 crores, growing 21% YoY. Despite operating challenges, own product sales grew 11% YoY. Margins were impacted by elevated raw material and energy prices, Chinese competition, and deferred demand.

Looking Ahead

Hikal Limited is expected to improve in H2, supported by API recovery, CDMO pipeline conversion, and improved agrochemical CDMO demand. The company remains confident in its growth outlook in H2 versus last year and reiterates its full year guidance of mid teens growth in Revenue and a substantial improvement in profitability.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Hikal Limited

Hikal Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Hikal holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 4 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 60% of its 52-week range with RSI at 48. In other words, neither side has a clear edge right now. The stock holds up despite -5.4% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Hikal Limited.

Kopran Limited (NSE: KOPRAN) has released its quarterly investor presentation for Q2 FY 2026-27, showcasing significant financial and operational highlights. The company, a global pharmaceutical powerhouse, reported robust revenue growth and operational performance across its API and Formulation segments.

Financial Highlights

The company’s revenue from operations for Q2 FY 2026-27 stood at Rs. 21,126 lakhs, marking a substantial increase from Rs. 15,399 lakhs in the same period last year. The EBITDA for the quarter was Rs. 1,822 lakhs, reflecting a healthy margin of 8.62%. Despite a forex loss of Rs. 219 lakhs, the net profit for the quarter was Rs. 439 lakhs, indicating a strong financial performance.

Operational Performance

Kopran Limited’s API segment continued to drive growth, with the company’s Atenolol and Carbapenem products leading the charge. The Formulations segment also performed well, with significant contributions from Anti-Diabetic and Anti-Hypertensive products. The company’s state-of-the-art manufacturing facilities in Maharashtra and Gujarat ensured high compliance with global regulatory standards.

Looking Ahead

Kopran Limited remains committed to driving sustainable growth through strategic imperatives such as capacity expansion, regulatory compliance, and cost optimization. The company’s focus on R&D and capacity enhancement positions it well for future growth and sustainability in the pharmaceutical industry.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Kopran Limited

Kopran Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Kopran gains 33.2% over three months and trades near its 52-week highs. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. Buyers show up with 5.0x the volume of sellers. Moreover, they dominated on 18 of recent sessions versus 12 for sellers — a healthy accumulation pattern. The stock rises 33.2% in three months. Yet revenue grows at only 7.2% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Kopran Limited.

Emcure Pharmaceuticals Limited (NSE: EMCURE) showcased a robust performance in Q2FY27 with a 24.3% year-on-year operating revenue growth and a 29.3% PAT growth. The company’s disciplined execution and complex science have driven this compounding value. The operating revenue reached INR 28,205 Mn, while the PAT stood at INR 3,251 Mn. Notably, the EBITDA grew by 30.9% year-on-year, marking a 103 bps YoY improvement.

Domestic Business Performance

The domestic business continued its double-digit growth for the second consecutive quarter, improving from 10% in Q1FY27 to 12% in Q2FY27. Key brands such as Orofer XT, Orofer FCM, Rosuvas EZ, and Vylda showed significant growth, with Orofer XT and Orofer FCM growing by 39% each. Zuventus also demonstrated good traction with anchor brands like Zostum and Bevon growing by 34% and 17% respectively.

International Business Performance

Internationally, the company delivered strong performance across the UK, EU, and Canada. The RoW segment saw a growth acceleration supported by new launches in LATAM, CIS, Asia, and Africa. The company’s product pipeline provides visibility for sustained medium-term growth. The company expects continued growth over the full year as its strengthened team and portfolio gain traction.

Emcure Pharmaceuticals Limited remains committed to its strategic vision and continues to simplify its group holding structure to achieve synergies in backend operations and corporate functions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Emcure posts a 2.1% three-month gain, but softens in the last few weeks. The business compounds revenue at 15.4% and profits at 20.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 5.8% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The business grows revenue at 15.4% and profits at 20.2%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 1.69 premium is usually justified. Check Fundamentals of Emcure Pharmaceuticals Limited.